Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Gastrointestinal Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3624)
News
Trials
Search handles
@ADesaiMD
@AGangiMD
@AJacomeMD
@APassaroMD
@AS7RAS
@A_CT_SimMDJD
@AaronGoodman33
@Amitmahipal79
@AnaVManana
@AndresC27622123
@AndresFCardonaZ
@ArndtStahler
@ArndtVogel
@AshaKarippot
@AshwinShindeMD
@AudreyKamMD
@AyasunMDPhD
@Aydah_AlAwadhi
@BallenDF
@BasselElRayesMD
@BatistaTP
@BenWestphalen
@BenjaminBesseMD
@Benjohnson1112
@BernhardDolesc1
@Betzabe100
@BiachiTiago
@BijoyTelivala
@BruixolaGema
@BrunoBockorny
@CadranelJ
@CamilaBragancaX
@CanerSaygin
@CathyEngMD
@CharlesJiangMD
@CharuAggarwalMD
@ChelseaPinnix
@ChrisHeery
@ChristianRolfo
@CtiaGaspar8
@DanChenMDPhD
@DanZhaoMD
@DavidSteensma
@DenboJw
@DerekAOReilly
@DocCatenacci
@DocDustyD
@DocMCotant
@DocOnco
@DoctorJSpicer
@DrBonillaOnc
@DrChoueiri
@DrChowdharyMD
@DrCraigGedye
@DrCrystalD
@DrEmmaHolliday
@DrEstfan
@DrEzraCohen
@DrGPrakash
@DrJNaidoo
@DrJashDatta
@DrMarkAwad
@DrMhidalgo
@DrMiguelPerales
@DrMirallas
@DrOlaLandgren
@DrR_DUNNE
@DrRanaMcKay
@DrSGraff
@DrShubhamPant
@DrSpratticus
@DrSteveMartin
@DrSukeshiArora
@DrVijayPatil11
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_JJ_Berenguer
@Dr_RShatsky
@Dr_R_Kurzrock
@DrewMoghanaki
@DucreuxMichel
@ESchattner
@EileenMOReilly
@EnriqueSoto8
@ErikaHamilton9
@FASinicropeMD
@FAndreMD
@FernandoOnco
@FilipHerpe
@FilipJankuMD
@FilippoPietran4
@FlavioRochaMD
@FogacciJoao
@FunchainMD
@GABOUALFA
@GI_RadOnc
@GIcancerDoc
@G_LipositsMD
@GabrielleVanRam
@GarciaOlmoD
@GarridoLagunaMD
@Geeky_Foodie
@GervasoLorenzo
@GillSharlene
@GlopesMd
@HCCvPDAC
@HH_Oncodr
@HHorinouchi
@HKennecke
@HalletJulie
@HassanSheikh_MD
@HenningWillers
@HosseinTaghiz11
@ILSONDavid
@IbrahimSahinMD1
@Inma__Gallego
@JDekervel
@JTrentMDPhD
@Ja_Capdevila
@JackWestMD
@JavleMilind
@Jbauml
@JenSeligmann
@JeremyLDavisMD
@JiaJennyLiu
@JoeChaoMD
@JohnRTMonsonMD
@JoshuaRichterMD
@KReissMD
@KSainiMD
@KellyBorgesAra2
@KimmieNgMD
@KlempnerSam
@KoheiShitara
@KrishanJethwa
@Kristel_GT
@KristenCiombor
@LAbushahin
@LFerri123
@LesinskiLab
@Liz_ORiordan
@LizzySmyth1
@LorenzaRimassa
@LuisCB_MedPharm
@LuisERaez1
@LujanPomponio
@MHadziMD
@MLJohnsonMD2
@MLPOncoData
@MPishvaian
@MadisonConces
@MaenAbdelrahim
@Maherjane
@ManniMD1
@MansfieldPaul
@MarkYarchoan
@MayCho_MD
@MelPalMD
@MichalisLiontos
@MiteshBorad
@MoniquMeneses
@Myeloma_Doc
@MyriamChalabi
@NDeVitoMD
@NVijayvergiaMD
@NagiSaghir
@NancyYouMD
@NataliyaUboha
@NicholasZaorsky
@NicoleKuderer
@NievesM42607618
@NiuSanford
@OlofssonBagge
@OmidHamidMD
@OncoThor
@OsamaRahma2
@PAscierto
@PGrivasMDPhD
@PTarantinoMD
@PamelaKunzMD
@ParikhSimul
@PatelOncology
@PatrickHwuMD
@PestanaRC
@PeterHoseinMD
@PrajnanDasMD
@ProfDMThomas
@RHuneburg
@RManochakian
@RachelRiechelm2
@RenoHemonc
@Rfonsi1
@Rndubois
@RussellPetty19
@RuthHe12
@RyanMoyMDPhD
@RyanNipp
@SKabrajiMD
@SKamath_MD
@SalemGIOncDoc
@SamLubner
@SamWangMD
@Sarbaji85064063
@ShaalanBeg
@ShepardDale
@SirohiBhawna
@SorenBentzen
@SprakerMDPhD
@StephenVLiu
@Sushilberiwal
@SuyogCancer
@SyedAAhmad5
@TamaraSN2
@TaniguchiMD
@Thalcin
@The_Big_Bach
@TiansterZhang
@TimothyJBrownMD
@TomFlaigMD
@Transplant_Doc
@TurgemanIlit
@UmutDisel
@UroDocAsh
@VanMorrisMD
@VivekSubbiah
@VoglNY
@WasifSaifMD
@WuGiOnc
@XiaotianJulie
@YJanjigianMD
@_ShankarSiva
@aLwOmbaT
@aakonc
@adapthyun
@aftimosp
@ahmadalhader
@angelopirozzi3
@anita_turk
@antoniomarraMD
@antonyruggeri
@anu_iris
@anup_kasi
@aparna1024
@badrinabeel
@barriere_dr
@benjiwal
@benweinbergmd
@bin_abeid
@binayshah
@bmassutis
@bpellegrino89
@bpiperdi
@bruixj
@cancerassassin1
@carlosbon78
@cczielinski
@chadinabhan
@christine_lovly
@cinthiavgauna
@cissamathias
@clacardone
@davidhenrymd
@dawood_findakly
@debby_keller
@doctorC369
@doctorpemm
@dr_yakupergun
@dralanburguete
@drallysonocean
@drenriquegrande
@drgandara
@drjasonstarr
@drjgauthier
@drkomanduri
@drkpavithran
@drlauragoff
@drlw2309
@drteplinsky
@drymtn
@dschan02
@duiliorocha_onc
@elmodir
@fedenichetti
@fernandbteich
@freddyeescorcia
@g_mountzios
@gabe_a_brooks
@gary_lyman
@gerryhanna
@guildsman
@guptaarjun90
@heinrich_kat
@helops79
@hemoncwarner
@ilyassahinMD
@isteddos
@j_luh
@jamecancerdoc
@jasonlukemd
@jaypsv
@jeffyoriomd
@jeremielefevre
@jesusanampa
@jgong15
@jimhumd
@jonathanloree
@jordanberlin5
@jpaArmand
@jrgralow
@jryckman3
@jsoriamd
@kharofaJ
@khkbao
@kimtruss
@kmody29
@ldawsonmd
@lindamahj
@loconte
@majorajay
@malkadav
@manalipatelmd
@marklewismd
@maryam_lustberg
@medoncdoc
@mgfakih
@mihaela_aldea
@montypal
@mpdrc
@mraphaelmd
@mtmdphd
@n8pennell
@naborala
@neerajaiims
@oncoOuLungCA
@oncologician
@outliersbio
@p_ciracimd
@pashtoonkasi
@protoninfo
@rachnatshroff
@radioncoluis
@ramyathota1
@rbryanbell
@rcarvalhoonco
@rdoebele
@realbowtiedoc
@rschilsky
@rsm2800
@ryanhuey
@saadvikdr
@schoffski
@scottrberry
@sejadiMD
@sepideh_gholami
@shilpaonc
@singhv2003
@skopetz
@smitha42
@subatomicdoc
@sundar__raghav
@tehfem
@tfleitask
@the_danielahn
@tmprowell
@tpjmd
@venkymd
@wangyub
@weldeiry
@weoncologists
@zapatalaguadomd
@zpyeung
Search handles
@ADesaiMD
@AGangiMD
@AJacomeMD
@APassaroMD
@AS7RAS
@A_CT_SimMDJD
@AaronGoodman33
@Amitmahipal79
@AnaVManana
@AndresC27622123
@AndresFCardonaZ
@ArndtStahler
@ArndtVogel
@AshaKarippot
@AshwinShindeMD
@AudreyKamMD
@AyasunMDPhD
@Aydah_AlAwadhi
@BallenDF
@BasselElRayesMD
@BatistaTP
@BenWestphalen
@BenjaminBesseMD
@Benjohnson1112
@BernhardDolesc1
@Betzabe100
@BiachiTiago
@BijoyTelivala
@BruixolaGema
@BrunoBockorny
@CadranelJ
@CamilaBragancaX
@CanerSaygin
@CathyEngMD
@CharlesJiangMD
@CharuAggarwalMD
@ChelseaPinnix
@ChrisHeery
@ChristianRolfo
@CtiaGaspar8
@DanChenMDPhD
@DanZhaoMD
@DavidSteensma
@DenboJw
@DerekAOReilly
@DocCatenacci
@DocDustyD
@DocMCotant
@DocOnco
@DoctorJSpicer
@DrBonillaOnc
@DrChoueiri
@DrChowdharyMD
@DrCraigGedye
@DrCrystalD
@DrEmmaHolliday
@DrEstfan
@DrEzraCohen
@DrGPrakash
@DrJNaidoo
@DrJashDatta
@DrMarkAwad
@DrMhidalgo
@DrMiguelPerales
@DrMirallas
@DrOlaLandgren
@DrR_DUNNE
@DrRanaMcKay
@DrSGraff
@DrShubhamPant
@DrSpratticus
@DrSteveMartin
@DrSukeshiArora
@DrVijayPatil11
@DrYukselUrun
@Dr_Ivanoncologo
@Dr_JJ_Berenguer
@Dr_RShatsky
@Dr_R_Kurzrock
@DrewMoghanaki
@DucreuxMichel
@ESchattner
@EileenMOReilly
@EnriqueSoto8
@ErikaHamilton9
@FASinicropeMD
@FAndreMD
@FernandoOnco
@FilipHerpe
@FilipJankuMD
@FilippoPietran4
@FlavioRochaMD
@FogacciJoao
@FunchainMD
@GABOUALFA
@GI_RadOnc
@GIcancerDoc
@G_LipositsMD
@GabrielleVanRam
@GarciaOlmoD
@GarridoLagunaMD
@Geeky_Foodie
@GervasoLorenzo
@GillSharlene
@GlopesMd
@HCCvPDAC
@HH_Oncodr
@HHorinouchi
@HKennecke
@HalletJulie
@HassanSheikh_MD
@HenningWillers
@HosseinTaghiz11
@ILSONDavid
@IbrahimSahinMD1
@Inma__Gallego
@JDekervel
@JTrentMDPhD
@Ja_Capdevila
@JackWestMD
@JavleMilind
@Jbauml
@JenSeligmann
@JeremyLDavisMD
@JiaJennyLiu
@JoeChaoMD
@JohnRTMonsonMD
@JoshuaRichterMD
@KReissMD
@KSainiMD
@KellyBorgesAra2
@KimmieNgMD
@KlempnerSam
@KoheiShitara
@KrishanJethwa
@Kristel_GT
@KristenCiombor
@LAbushahin
@LFerri123
@LesinskiLab
@Liz_ORiordan
@LizzySmyth1
@LorenzaRimassa
@LuisCB_MedPharm
@LuisERaez1
@LujanPomponio
@MHadziMD
@MLJohnsonMD2
@MLPOncoData
@MPishvaian
@MadisonConces
@MaenAbdelrahim
@Maherjane
@ManniMD1
@MansfieldPaul
@MarkYarchoan
@MayCho_MD
@MelPalMD
@MichalisLiontos
@MiteshBorad
@MoniquMeneses
@Myeloma_Doc
@MyriamChalabi
@NDeVitoMD
@NVijayvergiaMD
@NagiSaghir
@NancyYouMD
@NataliyaUboha
@NicholasZaorsky
@NicoleKuderer
@NievesM42607618
@NiuSanford
@OlofssonBagge
@OmidHamidMD
@OncoThor
@OsamaRahma2
@PAscierto
@PGrivasMDPhD
@PTarantinoMD
@PamelaKunzMD
@ParikhSimul
@PatelOncology
@PatrickHwuMD
@PestanaRC
@PeterHoseinMD
@PrajnanDasMD
@ProfDMThomas
@RHuneburg
@RManochakian
@RachelRiechelm2
@RenoHemonc
@Rfonsi1
@Rndubois
@RussellPetty19
@RuthHe12
@RyanMoyMDPhD
@RyanNipp
@SKabrajiMD
@SKamath_MD
@SalemGIOncDoc
@SamLubner
@SamWangMD
@Sarbaji85064063
@ShaalanBeg
@ShepardDale
@SirohiBhawna
@SorenBentzen
@SprakerMDPhD
@StephenVLiu
@Sushilberiwal
@SuyogCancer
@SyedAAhmad5
@TamaraSN2
@TaniguchiMD
@Thalcin
@The_Big_Bach
@TiansterZhang
@TimothyJBrownMD
@TomFlaigMD
@Transplant_Doc
@TurgemanIlit
@UmutDisel
@UroDocAsh
@VanMorrisMD
@VivekSubbiah
@VoglNY
@WasifSaifMD
@WuGiOnc
@XiaotianJulie
@YJanjigianMD
@_ShankarSiva
@aLwOmbaT
@aakonc
@adapthyun
@aftimosp
@ahmadalhader
@angelopirozzi3
@anita_turk
@antoniomarraMD
@antonyruggeri
@anu_iris
@anup_kasi
@aparna1024
@badrinabeel
@barriere_dr
@benjiwal
@benweinbergmd
@bin_abeid
@binayshah
@bmassutis
@bpellegrino89
@bpiperdi
@bruixj
@cancerassassin1
@carlosbon78
@cczielinski
@chadinabhan
@christine_lovly
@cinthiavgauna
@cissamathias
@clacardone
@davidhenrymd
@dawood_findakly
@debby_keller
@doctorC369
@doctorpemm
@dr_yakupergun
@dralanburguete
@drallysonocean
@drenriquegrande
@drgandara
@drjasonstarr
@drjgauthier
@drkomanduri
@drkpavithran
@drlauragoff
@drlw2309
@drteplinsky
@drymtn
@dschan02
@duiliorocha_onc
@elmodir
@fedenichetti
@fernandbteich
@freddyeescorcia
@g_mountzios
@gabe_a_brooks
@gary_lyman
@gerryhanna
@guildsman
@guptaarjun90
@heinrich_kat
@helops79
@hemoncwarner
@ilyassahinMD
@isteddos
@j_luh
@jamecancerdoc
@jasonlukemd
@jaypsv
@jeffyoriomd
@jeremielefevre
@jesusanampa
@jgong15
@jimhumd
@jonathanloree
@jordanberlin5
@jpaArmand
@jrgralow
@jryckman3
@jsoriamd
@kharofaJ
@khkbao
@kimtruss
@kmody29
@ldawsonmd
@lindamahj
@loconte
@majorajay
@malkadav
@manalipatelmd
@marklewismd
@maryam_lustberg
@medoncdoc
@mgfakih
@mihaela_aldea
@montypal
@mpdrc
@mraphaelmd
@mtmdphd
@n8pennell
@naborala
@neerajaiims
@oncoOuLungCA
@oncologician
@outliersbio
@p_ciracimd
@pashtoonkasi
@protoninfo
@rachnatshroff
@radioncoluis
@ramyathota1
@rbryanbell
@rcarvalhoonco
@rdoebele
@realbowtiedoc
@rschilsky
@rsm2800
@ryanhuey
@saadvikdr
@schoffski
@scottrberry
@sejadiMD
@sepideh_gholami
@shilpaonc
@singhv2003
@skopetz
@smitha42
@subatomicdoc
@sundar__raghav
@tehfem
@tfleitask
@the_danielahn
@tmprowell
@tpjmd
@venkymd
@wangyub
@weldeiry
@weoncologists
@zapatalaguadomd
@zpyeung
Filter by
Latest
9ms
Nice shoutout to Dr @RonaYaeger trial Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer NCT05710406 public post w/ more info https://t.co/hbemZq4P6a #gdugi2023 (@fireflyann)
9 months ago
Surgery
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9ms
Researchers are studying several alterations in pancreatic cancer, among them the BRAF mutation. One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian @MPishvaian. https://t.co/jSMKge2aYR (@letswinpc)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9ms
👀 217 patients with FGFR 1-4 alteration ➡️2 median prior systemic therapies 🚨ORR: 29.5% (Prior Therapy ORR 10%) ➡️Pancreatic cancer: 55.6% ➡️Biliary Tract Cancer: 51.6% ➡️Breast Cancer: 31% …. And many more @OncoAlert @VivekSubbiah @OncBrothers @curecc (@DrShubhamPant)
9 months ago
Clinical
|
FGFR1 (Fibroblast growth factor receptor 1)
9ms
Researchers are studying several alterations in pancreatic cancer, among them the BRAF mutation. One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian @MPishvaian. https://t.co/jSMKge2aYR #TumorBoardTuesday (@letswinpc)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9ms
The @lustgartenfdn recently highlighted #BCCPC collaborator @MPishvaian's work leading a study targeting a BRAF mutation in patients with #PancreaticCancer at @JohnsHopkins Great work Dr. Pishvaian! https://t.co/L9ojMLrRjh (@OHSUpancreatic)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9ms
YUP!She updated me on a new trial for my RET mutation just before my pancreatic cancer returned. Stage 4 in liver/lungs.Been following me with regular liquid biopsies & tumor markers.Started the trial.Meds killed the cancer in 30 days!! PM me. (@randyeringler)
9 months ago
Liquid biopsy • Metastases • Biopsy
|
RET (Ret Proto-Oncogene)
|
RET mutation
9ms
Things may be looking up in #coloncancer care as data from ongoing trials is uncovered. Explore metastatic #colorectalcfancer further with Dr. Charles Turck as he speaks with @MoffittNews’ Dr. Richard Kim and @benweinbergmd from @MedStarHealth: https://t.co/XtIKiAH16R (@ReachMD)
9 months ago
Metastases
|
FANCE (FA Complementation Group E)
9ms
In the phase 3 GLOW trial, CAPOX plus zolbetuximab significantly improved progression free survival and overall survival in patients with CLDN18.2+, HER2- untreated #GastricCancer or gastroesophageal junction adenocarcinoma @AstellasUS @mdmanishshah https://t.co/YYbLHhiyOq (@NatureMedicine)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative
|
Vyloy (zolbetuximab)
9ms
The GLOW study is published! Kudos to the GI Oncology community and our patients. Zolbetuximab should be considered a standard option for CLDN18.2 positive gastroesophageal adenocarcinoma! @drallysonocean @pashtoonkasi @nyphospital @WCM_MeyerCancer https://t.co/G0wWPLz2Zr (@mdmanishshah)
9 months ago
Clinical
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
Vyloy (zolbetuximab)
9ms
Congratulations @mdmanishshah & team on these GLOWing 💡💡🌟🌟 results & for so brightly changing the standard treatment for patients with #claudin18point2 #gastroesophageal #cancer ! #MedEd #MedX #MedTwitter (@drallysonocean)
9 months ago
Clinical
|
CLDN18 (Claudin 18)
9ms
ASCI member @ARustgi @ColumbiaCancer in @JCI_insight: LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3: https://t.co/Y3cVAu3zAu #Gastroenterology #Oncology (@the_asci)
9 months ago
NOTCH3 (Notch Receptor 3) • CLDN1 (Claudin 1) • LIN28B (Lin-28 Homolog B)
9ms
LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3: https://t.co/JIvStFdT5H @ARustgi @ColumbiaCancer #Gastroenterology #Oncology (@JCI_insight)
9 months ago
NOTCH3 (Notch Receptor 3) • CLDN1 (Claudin 1) • LIN28B (Lin-28 Homolog B)
9ms
Super exciting! Let’s go @break_cancer Let’s move the needle for 🔥🔥#KRAS #PancreaticCancer #CancerResearch Trial is ongoing!! @EileenMOReilly @MSKCancerCenter (@CentralParkWMD)
9 months ago
KRAS (KRAS proto-oncogene GTPase)
9ms
Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer https://t.co/G5fIaMjHOe via @onclive (@marciasgreen)
9 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
9ms
🎥@GABOUALFA (@MSKCancerCenter) highlights exciting anti-TIGIT therapies for hepatocellular carcinoma. Promising results from MORPHEUS-Liver trial with tiragolumab, atezolizumab, and bevacizumab: ➡️https://t.co/hR1dCQJTBi⬅️ #ASCO23 #Oncology #ImmunoOnc (@VJOncology)
9 months ago
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
9ms
In @CCR_AACR #Researchpaper by @KReissMD & team on reversions in BRCA/PALB2 ✅ #PancreaticCancer #patients treated w PARPi❌ ⚠️ Reversions led to💊resistance & poor outcome. #PrecisionMedicine @OncoAlert 🚨#pancsm 💜 @KenOliveLab @quimmateo @Aiims1742 https://t.co/bAfvFLKonR (@BenWestphalen)
9 months ago
Clinical
|
PALB2 (Partner and localizer of BRCA2) • BRCA (Breast cancer early onset)
9ms
What gets paid for!? I remember having a HER2 3+ gastric cancer guy about 12 years ago. Got all better on Herceptin, but after 20 months there was progression. Couldn't get a second line therapy paid for. How do you do it? (Couldn't get free drug either). (@davideyoungmd)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Herceptin (trastuzumab)
9ms
Researchers are studying several alterations in pancreatic cancer, among them the BRAF mutation. One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian (@MPishvaian). https://t.co/jSMKge2aYR (@letswinpc)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
9ms
We had summarized some of the HER2 data in colorectal cancer. The space in cholangiocarcinoma is quickly expanding with bispecifics and other drugs as mentioned. Choose/pivot to #clinicaltrials. If not available, choose something that has ✅blood brain barrier 🧠 penetration. https://t.co/9HKqjJ8EkS (@pashtoonkasi)
9 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
9ms
“Evolving Landscape of Targeted Treatment Options for HER2-Positive Gastric/Gastroesophageal Adenocarcinomas” by Raisa Epistola, MD, Joseph Chao, MD, and Jennifer Lee, MD https://t.co/lPI7BsMr8o @JoeChaoMD @HarborUCLA @cityofhope (@clinadvances)
9 months ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
9ms
Featured today by @MSKLibrary: #SMARCA4 Mutations in #Carcinomas of the Esophagus, #Esophagogastric Junction, and Stomach: https://t.co/SRdw4D48zS @alexanderjneil @JamesClearyMD @feidng (@MSKLibrary)
9 months ago
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
|
SMARCA4 mutation
9ms
The BRAF V600E mutation in #coloncancer carries distinct implications and affects 5-15% of cases, leading to a poorer prognosis. Learn about the latest #treatment strategies and expert insights from Dr. Rona Yaeger at #ASCO23. @RonaYaeger https://t.co/Jn6B8zYvYS (@oncologytube)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
9ms
During the GI Cancer Committee session, Dr. Thom George provides an update on the GI004 COMMIT study, currently enrolling patients with metastatic adenocarcinoma of the colon or rectum. This is the last session of #NRG2023. @TGeorgeMD (@NRGonc)
9 months ago
Clinical • Metastases
|
NRG2 (Neuregulin 2)
9ms
I’m spoiled➡️Rectal Cancer Trial options: ✔️an investigator trial of AB928 Dual Adenosine Receptor Antagonist💊➕AB122 (a PD1⛔️) (PANTHER)➕☢️ ✔️JANUS @JoshSmithMDPhD @ALLIANCE_org 🔌 ✔️ROBIN 💡Add preference for short course☢️in oligo-metastatic to avoid breaks. #CRCSM (@pashtoonkasi)
9 months ago
Metastases
|
PD-1 (Programmed cell death 1)
|
Yutuo (zimberelimab) • etrumadenant (AB928)
9ms
Didn't make it to #ASCO23? Check out what you missed! Now available, useful #GICancers Practice Aids from our activity with Drs. Elena Elimova, Geoffrey Ku, and Shubham Pant (@DrShubhamPant): https://t.co/vlqXjYiCsL #BTC #GEA #HER2 #MedEd #MedTwitter (@PeerView)
9 months ago
HER-2 (Human epidermal growth factor receptor 2)
9ms
Case report by @BenWestphalen @heinrich_kat et al. discussing a patient with #pancreaticcancer bearing a BRAF fusion, leading to MAPK activation, MLHph and finally MSI with response to #immunotherapy ➡️ https://t.co/7v9D0VuQQo #pancsm #immunoonc (@JCOPO_ASCO)
9 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF fusion
9ms
Perfectly timed mentor-mentee paper in @CCR_AACR from @TimothyJBrownMD & @KReissMD The Clinical Implications of Reversions in Patients with Advanced #PancreaticCancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib https://t.co/rzYy2fOk24 (@Aiims1742)
9 months ago
Clinical • Metastases
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2)
|
Rubraca (rucaparib)
9ms
Never - only had I lived in AZ, would have honked. @GIcancerDoc (@chadinabhan)
9 months ago
9ms
Register by Aug 16 to get the lowest rates for the AACR Special Conference on Pancreatic Cancer (Sept 27-30, Boston), chaired by Christine A. Iacobuzio-Donahue, Anirban Maitra, Rosalie C. Sears, and Jen Jen Yeh. https://t.co/CmNGJOGJD3 #AACRpan23 @ciacobu @Aiims1742 @SearsRosie (@AACR)
9 months ago
9ms
#Tucatinib + #Trastuzumab was approved earlier this year for refractory mCRC HER 2 positive disease. Previously, we had also discussed the implications of anti-egfr therapy w/ @GIcancerDoc and @CathyEngMD in this subset + RAS WT. This study by @GIcancerDoc continues to support:… https://t.co/16FDqtJdMS (@OncBrothers)
9 months ago
HER-2 positive • RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
9ms
#EOCRC #EAOCRC @Lynchsyndromirl @FightCRC @CGAIGC @insightmeeting @IEColonCancer @CRCequity @TheColonClub @AGA_Gastro @ASCO @ASCOPost @AACR (@FASinicropeMD)
9 months ago
9ms
Great work by the team around @FilippoPietran4, @ChiaraCrem1 and @sara_lonardi1 investigating ICI in dMMR #colorectalcancer 👉TMBhigh: excellent response 👉TMBlow: poor response 👉more biomarkers needed for TMB intermediate 🧐 @OncoAlert 🚨 https://t.co/lBveXH6apZ (@heinrich_kat)
9 months ago
TMB (Tumor Mutational Burden)
|
MSI-H/dMMR • TMB-L
9ms
Huge congrats to @JohnDKaralisMD and @SamWangMD . Gastric cancer dream team with another impressive project 👏🏾👏🏾 (@GilbertZMurimwa)
9 months ago
9ms
Register today to join @ESSOnews and SSO on August 18th for an in-depth case-based conversation on Multimodality Management of #PancreaticCancer. Register at https://t.co/LznA34P2LA @HalletJulie @AlexParikhMD @PatricioPolanc0 @e_rangelova @DrJasonWillis (@SocSurgOnc)
9 months ago
9ms
And yet we have update to NCCN for dMMR colon cancer with ICI, based on less numbers and very short follow up 🤷♂️ Let’s not try to make a L from what is clearly a W. We need a STABLE-MATES type trial of SBRT + IO vs. sublobar/lobar resection. Organ preservation! (@5_utr)
9 months ago
MSI-H/dMMR
9ms
Our review on targeted/IO strategies in HER2+ve gastric/GEJ adenocarcinomas is out now in @JIPOEditors. As always, it has been a delight working with Dr. @AnwaarSaeed3! https://t.co/sUida2A4lt (@HMAbushukair)
9 months ago
Review
|
HER-2 (Human epidermal growth factor receptor 2)
9ms
Check out our recent research study on hepatic adenoma subtypes and their imaging findings at gadoxetate disodium-enhanced MRI! @StanfordRad @StanfordBodyRad @RadiologyUcla @StevenSRaman_MD (@justintsemd)
9 months ago
9ms
Join us in congratulating @PeterHoseinMD! Dr. Hosein was recently announced as a Pancreatic Cancer Action Network (@PanCAN) Scientific & Medical Advisory Board member. Read more: https://t.co/FQh8EzWQJl (@SylvesterCancer)
9 months ago
9ms
Association of Genetic Ancestry with Molecular Tumor Profiles in Colorectal Cancer {preprint} [Jul 12, 2023] @RheadBrooke et al. @ribozyme @NiuSanford @medrxivpreprint https://t.co/T70g0XLmXF #GeneticCounselors #crcsm #PrecisionMedicine @UTSWNews @TempusLabs (@mtmdphd)
9 months ago
Preprint
9ms
7/Key Study Findings🔑 🌟Patients >75yr had very🔽low rate (0.2%) of invasive colorectal adenocarcinoma 🦀 🌟Invasive CRC🦀 patients with a life expectancy <10 years: only 1 of 9 received 🦀 treatment 🌟Patients >85yr had⬆️adverse 🚫event rate @ 10 days 🟰⬆️Risk ⬇️Benefit (@Montalvan214)
9 months ago
Clinical • Adverse events
9ms
Despite the high prevalence of KRAS mutations in pancreatic cancers, a limited number of cases harbor an actionable point mutation. @EileenMOReilly @MSKCancerCenter #pancsm https://t.co/7uqF6ZMfTU (@OncLive)
9 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
9ms
On this JCO Precision Oncology Conversations podcast episode, host @thenasheffect speaks w/ Dr. Alicia Latham about her #JCOPO article, Prevalence & Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients w/ Lynch Syndrome. https://t.co/pkgaCft9r2 #crcsm (@JCOPO_ASCO)
9 months ago
Clinical • Mismatch repair
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login